Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 20

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

364

HTML

3564

Figures (1-3)

181

Tables (1-3)

198

Sum=4307

May 28, 2010 (publication date) through Jul 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. May 28, 2010; 16(20): 2468-2475
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2468

Table 3 Summary of recommended therapeutic strategies for recurrent HBV infection after LT

Clinical setting	Recommended first line therapies	Recommended second line therapies
De novo HBV infection, wild-type HBV infection	LAM for short-term therapy; ADV for long-term therapy	ETV, TDF
LAM resistance	ADV, ADV + LAM	TDF
ADV resistance	ETV	TDF + LAM
Irreversible graft dysfunction	SLT

ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; SLT: Second liver transplantation.

Citation: Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475
URL: https://www.wjgnet.com/1007-9327/full/v16/i20/2468.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i20.2468